Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead Sciences's dividends per share for the
three
months ended in Mar. 2026 was €0.71. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was €2.74. Its Dividend Payout Ratio for the
three
months ended in Mar. 2026 was 0.40. As of today, Gilead Sciences's Dividend Yield % is 2.34%.
During the past 12 months, Gilead Sciences's average Dividends Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 2.70% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 3.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Gilead Sciences was 20.90% per year. The lowest was 2.70% per year. And the median was 6.30% per year.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Gilead Sciences (FRA:GIS) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Gilead Sciences's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as
During the past 13 years, the highest Dividend Payout Ratio of Gilead Sciences was 0.67. The lowest was 0.16. And the median was 0.39.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
Gilead Sciences Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.820000
2026-06-15
2026-06-15
2026-06-29
Cash Dividend
quarterly
USD:EUR 0.868000
USD 0.820000
2026-03-13
2026-03-13
2026-03-30
Cash Dividend
quarterly
USD:EUR 0.865000
USD 0.790000
2025-12-15
2025-12-15
2025-12-30
Cash Dividend
quarterly
USD:EUR 0.854000
USD 0.790000
2025-09-15
2025-09-15
2025-09-29
Cash Dividend
quarterly
USD:EUR 0.852000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Gilead Sciences's Dividend Yield (%) for Today is calculated as
Current Share Price is €119.00.
Gilead Sciences's Dividends per Share for the trailing twelve months (TTM) ended in Today is €2.7688.
During the past 13 years, the highest Dividend Yield of Gilead Sciences was 4.90%. The lowest was 2.03%. And the median was 3.48%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Dividends per Share Related Terms
Gilead Sciences Dividends per Share Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, AMGN, BMY: Dividends per Share Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Dividend Yield % falls into.
Gilead Sciences (FRA:GIS) has a Dividends per Share of €2.74 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Dividends per Share too high?
Gilead Sciences' current Dividends per Share is €2.74. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Dividends per Share compare to PFE and AMGN?
Gilead Sciences' Dividends per Share of €2.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Dividends per Share is €2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €85.24, compared to a current price of €119.00 — trading 39.6% above its estimated fair value. The current Dividends per Share is €2.74. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Dividends per Share is €2.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €119.00 is trading 39.6% above its estimated GF Value™ of €85.24.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Dividends per Share: €2.74
GF Value™: €85.24 vs. price of €119.00 (39.6% above fair value)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score
Get the complete analysis for FRA:GIS
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
